Cord Blood transplant outperforms bone marrow transplant states
a new study by ASH
- Published in the journal – Blood Advances – the studies aim to study the efficacy of
cord blood in treatment of diverse disorders
- Studies’ outcome crucial for multi-ethnic country like India, where the chances of finding a
matching donor are very low.
National, 30th March 2021:
American Society of Hematology (ASH), the world's largest
professional society working to conquer blood diseases has recently released two key
studies on cord blood transplants, as part of its Blood Advances journal. Led by a team of
leading researchers from University of Colorado and University of Pittsburgh, the two
studies have brought to foray the various benefits of cord blood transplant over bone
marrow in cancerous and non-cancerous disorders. With the growing concerns among
medical fraternity about finding matching bone marrow donors in a multi-ethnic country
like India, the findings of the studies clearly outline the efficacy of cord blood in the
treatment of diverse disorders.
In the study conducted to weigh benefits of cord blood transplant over bone marrow
transplant for cancerous disorders, University of Colorado researchers compared the
outcomes of matched bone marrow and double-unit cord blood transplants in adults.
Amongst the 313 patients studied (190 cord blood transplant and 123 matched related
donor transplant patients), the two key findings emerged. One, Chances of developing graft
versus host disease were higher with bone marrow as compared to cord blood transplants
and two, it was discovered that relapse rates were lower in patients who received a cord
Followed by the findings of the first study, a second study on the efficacy of cord blood
transplant among non-cancerous disorders was also undertaken by a team of researchers
from University of Pittsburgh. The researchers successfully treated 44 children suffering
from various non-cancerous & immune disorders with a combination of low dose
chemotherapy and single-unit of HLA-mismatched cord blood with no cell expansion. The
successful outcomes provided by this first of its kind and the largest trial showed that cord
blood outperformed bone marrow in terms of graft failure, treatment related mortality and
event-free survival. Also, this gives tremendous confidence to patients & doctors in a multi-
ethnic country like India where the chances of finding a matching donor are very low.
Commenting on this, Dr. Sunil Bhat, MBBS, MD (Pediatrics) Mazumdar Shaw Cancer
Centre, Narayana Health City, Bengaluru said, “Authors have tried a new conditioning
regimen which is "reduced toxicity" hence less toxic to the patients but at the same time
quite effective resulting into good outcomes in these difficult disease conditions. The application of "immune boost" post-transplant is also novel and results into better immune
recovery and less complications especially of infections post cord blood transplant.”
“Another study which was published during same year gives a clear understanding on how
to select a cord blood donor based on Human Leukocyte Antigens (HLA) match and also
makes clear recommendations on the stem cell dose required for successful transplant. This
study is also a great guide to the physicians to select cord blood donors for transplant
Other key highlights from the studies:
Study 1 – To understand the efficacy of Cord Blood transplants over bone marrow for
Outcomes of this study demonstrated that cancer patients undergoing cord blood
transplants showed better improvement & developed lesser complications than
those who received matched sibling donor transplants.
The overall improved recovery rate and lack of complications resulted in low costs
associated with post-transplant care.
- This treatment protocol had a distinct positive impact on the patients’ quality of life.
Study 2 – To understand the efficacy of Cord Blood transplants over bone marrow for non-
- The graft failure rate of <5% seen in this trial is the lowest ever reported for non-
manipulated cord blood grafts in non-cancerous or even in cancerous diseases.
- The lowest 1-year (Treatment-Related Mortality) TRM of 5%, resulting in >90% Event
Free Survival (EFS) at 1 year was reported.
- A single unit of allogeneic cord blood could be identified for each of the 44 eligible
children regardless of their ethnicities, showing the unique and unparalleled
suitability of cord blood grafts even without being perfectly (HLA) matched.
- No cell expansion was required in the trial. In general, a single cord blood unit
doesn't have sufficient stem cells to treat adults.
- No patient developed severe chronic graft versus host disease and a distinct
improvement in the quality of life was reported.
- The novel treatment protocol used in the trial prevented graft failure and aided
Established in 2004, LifeCell is India’s first and largest stem cell bank, enjoying the
trust of over 3,50,000+ parents who have banked their children’s stem cells with the company. We
are the only player in the industry providing comprehensive stem cell solutions including the novel
initiative of community stem cell banking, R&D and point-of-care stem cell therapy for orthopaedic
and vascular specialities. Our Diagnostic division offers India’s most comprehensive diagnostic
program for mother & baby care, offering preconception, prenatal and newborn testing services aimed at addressing the challenge of high infant mortality rate in the country as well as promoting
health and wellness for generations to come.